Lymphoma

On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy developed by Kite Pharma (now part of Gilead Sciences).

Tecartus (brexucabtagene autoleucel), developed by Kite Pharma (now part of Gilead Sciences), is one such therapy that has gained significant attention for its efficacy in treating certain types of lymphoma and leukemia.

Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy, has revolutionized the treatment landscape for certain types of cancer.

On July 24, 2020, the US Food and Drug Administration (FDA) granted accelerated approval to Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Subsequently, on October 1, 2021, the FDA expanded the approval of Tecartus to include the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).

Tecartus (brexucabtagene autoleucel) has emerged as a revolutionary CAR-T cell therapy, gaining approval from the U.S. Food and Drug Administration (FDA) for the treatment of two critical hematologic malignancies.

Autologous and allogeneic stem cell transplantation (auto-SCT and allo-SCT) represent potential curative approaches for patients with T-cell lymphomas.

In early June 2024, the results of a Phase I clinical trial for the CD7-CAR-T product PA3-17 in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (r/r T-ALL/LBL) were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

The initial list price for Yescarta was set at approximately $373,000 per treatment.

Kymriah is a gene therapy treatment developed by Novartis Pharmaceuticals for certain types of blood cancers. It works by reprogramming the patient’s T cells to target and destroy cancer cells.

The National Cancer Institute (NCI) in the USA was the first to report a successful case of second-generation CD19 CAR-T cell therapy.

Kymriah, also known as tisagenlecleucel, is a revolutionary treatment in the field of oncology, specifically designed for certain types of blood cancers.